Recruiting

Percutaneous Intervention

Sponsor:

Nationwide Children's Hospital

Code:

NCT05547165

Conditions

Ductus Arteriosus, Patent

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Interventions

Percutaneous Patent Ductus Arteriosus Closure (PPC)

Responsive Management Intervention

Echocardiogram, cardiac

Study Details

Brief summary:

Patent Ductus Arteriosus is a developmental condition commonly observed among preterm infants. It is a condition where the opening between the two major blood vessels leading from the heart fail to close after birth. In the womb, the opening (ductus arteriosus) is the normal part of the circulatory system of the baby, but is expected to close at full term birth. If the opening is tiny, the condition can be self-limiting. If not, medications/surgery are options for treatment.

There are two ways to treat patent ductus arteriosus - one is through closure of the opening with an FDA approved device called PICCOLO, the other is through supportive management (medications). No randomized controlled trials have been done previously to see if one of better than the other. Through our PIVOTAL study, the investigators aim to determine is one is indeed better than the other - if it is found that the percutaneous closure with PICCOLO is better, then it would immediately lead to a new standard of care. If not, then the investigators avoid an invasive costly procedure going forward.

Conditions

Ductus Arteriosus, Patent

Study ID

NCT05547165

Start date

Feb 21, 2023

Status verified date

Mar, 2025

Completion date

Feb 28, 2026

Anticipated

Primary completion date

Feb 28, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. EPIs born between 22-weeks+0 days (220/7 wks) and 27-weeks+6 days (276/7 wks) gestation, inclusive
2. Admitted to a study NICU
3. Birth weight ≥700-grams
4. Mechanically ventilated at time of consent and randomization
5. HSPDA ("PDA Score" ≥6) noted on echocardiogram (ECHO)
6. Randomization is able to be performed within 5 days of the qualifying ECHO and when infant is 7-32 days postnatal

Exclusion Criteria:

Clinical Exclusion Criteria

1. Life-threatening congenital defects (including congenital heart disease such as aortic coarctation or pulmonary artery stenosis). PDA and small atrial/ventricular septal defects are permitted;
2. Congenital lung abnormalities, (e.g. restrictive lung disease);
3. Pharyngeal or airway anomalies (tracheal stenosis, choanal atresia);
4. Treatment for acute abdominal process (e.g., necrotizing enterocolitis);
5. Infants with planned surgery;
6. Active infection requiring treatment;
7. Chromosomal defects (e.g., Trisomy 18);
8. Neuromuscular disorders;
9. Infants whose parents have chosen to allow natural death (do not resuscitate order) or for whom limitation of intensive care treatment is being considered (e.g. severe intraventricular hemorrhage)
10. Physician deems that the infant would not be a Percutaneous PDA Closure candidate due to clinical instability; however, if the infant's clinical status improves before 30-days postnatal and all inclusion criteria are still met, then the infant may be enrolled.

ECHO-based Exclusion Criteria

1. Pulmonary hypertension (defined by ductal right to left shunting for >33% of the cardiac cycle) in which early PDA closure may increase right ventricular afterload and compromise pulmonary and systemic blood flow;
2. Evidence of cardiac thrombus that might interfere with device placement;
3. PDA diameter larger than 4 mm at the narrowest portion (consistent with FDA-approved instructions for Piccolo™ device use).
4. PDA length smaller than 3 mm (consistent with FDA-approved instructions for Piccolo™ device use).
5. PDA that does not meet inclusion requirements ("PDA Score" <6).\* \* If a potential participant is found to have a PDA meeting eligibility requirements on a subsequent ECHO during the required period of 7 - 30 postnatal days of age, they may then be declared eligible to participate and enrolled, provided all other inclusion criteria are met and exclusion criteria are not met.

Other Exclusion Criteria

1. Parents or legal guardian do not speak English or Spanish

Study Design

Enrollment

240 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: Primary Comparator

Interventional groups that subject will be randomly assigned to include Percutaneous Patent Ductus Arteriosus Closure (PPC) or Responsive Management. Those assigned to PPC will undergo active intervention to close a hemodynamically significant patent ductus arteriosus (HSPDA) whereas those assigned to Responsive Management will be treated to manage the symptoms of the HSPDA and permit natural closure over time.

other: Secondary Intervention

Sub-group of patients initially randomized to Responsive Management who may suffer a decline in health status that can be attributed to the presence of a hemodynamically significant patent ductus arteriosus (HSPDA). These patients, upon meeting pre-specified clinical criteria, will undergo active treatment via Percutaneous Patent Ductus Arteriosus Closure (PPC) as in the active comparator arm.

Interventions

Percutaneous Patent Ductus Arteriosus Closure (PPC)

Infants in this group will undergo catheter-based PPC closure ≤48 hours following randomization and within 7-days of qualifying ECHO. All participants assigned to PPC will receive the Amplatzer Piccolo™ Occluder which will be implanted within the duct (intraductal placement). The Piccolo™ occluder is approved by the US FDA for this purpose.

Responsive Management Intervention

Interventional PDA-closure, including PPC or surgical ligation and post-randomization pharmacologic (NSAID or acetaminophen) (enteral or intravenous) PDA treatment, are not allowed unless secondary treatment thresholds (see below) are met. Healthcare decisions for Responsive Management will be made at the discretion of the treatment team, while the infant is carefully monitored for any decline in status that may be attributed to the presence of PDA, in which case, Secondary Intervention (described below) may be considered.

Despite widespread acceptance of responsive PDA management, no consensus definition exists. The following Responsive Management interventions are permitted but not required per clinician discretion: 1) fluid restriction between 120-140 mL/kg/day; 2) diuretics (per local practice); 3) increases in positive end-expiratory pressure (PEEP).

Echocardiogram, cardiac

An echocardiogram, also known as "ECHO", is an ultrasound image of the heart. Echocardiography is a common test used for the diagnosis and management of cardiac diseases or conditions.

Primary outcome measure

  • Number of days free of ventilatory support requirement (ventilator-free days; VFDs) [ Time Frame: 30 days post-randomization ]

Central Contacts and Locations

Locations

University of Alabama

Recruiting

Birmingham, Alabama, United States, 35294

Contacts

Principal Investigator:

Andrea Kane, MD

Arkansas Children's Hospital

Recruiting

Little Rock, Arkansas, United States, 72202

Contacts

Megha Sharma, MD

MSharma@uams.edu

Sherry Courtney, MD

SECourtney@uams.edu

Cedars-Sinai Medical Center

Recruiting

Los Angeles, California, United States, 90048

Contacts

Evan Zahn, MD

Evan.Zahn@cshs.org

Kurlen Payton, MD

Kurlen.Payton@cshs.org

UC Davis Children's Hospital

Recruiting

Sacramento, California, United States, 95817

Contacts

Frank Ing, MD

ffing@ucdavis.edu

Joe DiMaggio Children's Hospital

Recruiting

Hollywood, Florida, United States, 33021

Contacts

Peter Guyton, MD

PGuyon@mhs.net

Bruce Schulman, MD

Brucesmd@aol.com

Orlando Health

Recruiting

Orlando, Florida, United States, 32806

Contacts

Ann and Robert H. Lurie Children's Hospital

Recruiting

Chicago, Illinois, United States, 60611

Contacts

Boston Children's Hospital

Recruiting

Boston, Massachusetts, United States, 02115

Contacts

St. Louis Children's Hospital

Recruiting

Saint Louis, Missouri, United States, 63110

Contacts

Daisuke Kobayashi, MD

daisuke@wustl.edu

Andy Glatz, MD

glatz@wustl.edu

Nationwide Children's Hospital

Recruiting

Columbus, Ohio, United States, 43205

Contacts

Le Bonheur Children's Medical Center

Recruiting

Memphis, Tennessee, United States, 38103

Contacts

Mark Weems, MD

mweems@uthsc.edu

Medical City Children's Dallas

Recruiting

Dallas, Texas, United States, 75230

Contacts

UT Southwestern Children's Medical Center of Dallas

Recruiting

Dallas, Texas, United States, 75235

Contacts

Texas Children's

Recruiting

Houston, Texas, United States, 77030

Contacts

Seattle Children's

Recruiting

Seattle, Washington, United States, 98105

Contacts

Kirti Upadhyay, MD

kupadhya@uw.edu

Children's Wisconsin

Recruiting

Milwaukee, Wisconsin, United States, 53226

Contacts

Vijay Karody, MD

vkarody@mcw.edu

Todd Gudausky, MD

dgudausk@mcw.edu

More Information

Sponsor

Nationwide Children's Hospital

Last update posted

Mar 30, 2025

Last verified

Mar, 2025

Keywords

  • PDA

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Nationwide Children's Hospital on 2025-03-30.